1. Xiao-Ying Xi, Li Wang, Aijun Liu* and Min-Fu Yang.Myocardial fibroblast activation imaging in light chain cardiac amyloidosis. .Journal of Nuclear Cardiology.2022.3(2).http://doi.org/10.1007/ s12350-022-02963-0.SCI |
2. Qingrong Pan, Yuan Jian#, Yeqing Zhang, Wenkai Zhang, Zhe Chen, Yanna Yang, Aijun Liu*, Guang Wang*. . The Association between low T3 Syndrome and Survival in Patients with Newly Diagnosed Multiple Myeloma: A retrospective Study. .Technology in Cancer Research & Treatment.2022.3(6).http://doi.org/10.1177/ 15330338-2210-94422.SCI |
3. Yongchao Liang, Ying Zhu, Ying Zhang, Ziwei Chen, Boyang Li, Aijun Liu* and Lihong Liu*.Clinical Observation and Pharmacoeconomic Evaluation of Original research drug and Generic drug Bortezomib in the treatment of Multiple Myeloma. Journal of Healthcare Engineering.Journal of Healthcare Engineering.2022.8(3).http://doi.org/10.1155/ 2022/5201354.SCI |
4. 殷佳慧,徐婷婷,王颖,陈文明,刘爱军.免疫麻痹对达深度缓解新诊断多发性骨髓瘤患者的预后意义.中华内科杂志.2022.61(10).1152-1157.SCI |
5. Jin Liu, Xiaoxia Hu, Yanchun Jia, Jin Lu, Jae Hoon Lee, Kihyun Kim, Wenming Chen, Aijun Liu, Yang Liu, Qi Chen, Chunyang Zhang, Cheolwon Suh, Min Kyoung Kim, fan zhou, Wee Joo Chng, Shaji Kumar, Brian Durie, Jian Hou*, Weijun Fu*, Juan Du*.Clinical features and survival outcomes in IgD myeloma: A study by Asia Myeloma Network (AMN).Leukemia.2020.10(16). DOI 10.5152.SCI |
6. Rastgoo N, Wu J, Liu A, Pourabdollah M, Atenafu E G, Reece D, Chen W, Chang H*.Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma.Haematologica.2019.227579.doi:10.3324.SCI |
7. 贾静,刘爱军*,陈文明,吴垠,李燕郴,冷芸,高文.RVD方案对新诊断MM患者缓解深度的研究.中国肿瘤临床.2019.46(14).734-738.核心期刊 |
8. 张飞龙#,刘爱军*.循环肿瘤游离DNA在B细胞肿瘤的研究进展.白血病.淋巴瘤.2018.31(9).231-235. |
9. Jing Jia # Huijuan Wang Miaomiao Wu Feilong Zhang Xuelin Liu Wenming Chen Aijun Liu* .Factor X Deficiency Caused by Nonsecretory Myeloma Successfully Corrected with Bortezomib:A Case Report and Review of the Literature .Acta Haematol .2018.140.46-50.SCI |
10. Lu Jin, Lu Jin#,Liu Ajun#, Fu weijun,Du Juan, Huang Xiaojun*,Chen Wenming*,Hou Jian*.The applicability of the international staging system in Chinese patients with multiple myeloma .BioMed research international.2015.3(1).doi: doi.10.1155/2015/856704.SCI |
11. 朱婉秋,刘爱军*,陈文明.调节性T细胞在多发性骨髓瘤的研究进展.白血病.淋巴瘤.2014.23(9).566-568. |
12. 刘爱军,李利红*.谈临床实习管理.中国病案.2012.6(8).51-52.核心期刊 |
13. Liu Aijun, Li Lihong*, Zong Hong,ZhaiYuhua, Yang Guangzhong, Chen Wenming.Significance of Oligoclonal Bands after Stem Cell Transplantation.Asian Pacific Journal of Cancer Prevention.2012.13(4).1483-1486.SCI |
14. 刘爱军,李利红*.血清游离轻链在多发性骨髓瘤诊断及疗效监测中的临床意义.白血病.淋巴瘤.2011.20(11).645-647.核心期刊 |
15. 刘爱军,李利红*,黄仲夏,张蕾,吴垠,李燕郴,高文,冷芸,王慧娟.彭替佐米、地塞米松加或不加沙利度胺治疗多发性骨髓瘤67例疗效分析.中华血液学杂志.2010.31(7).486-488.核心期刊 |
16. 刘爱军,李利红*,黄仲夏,张蕾.硼替佐米、地塞米松联合表柔比星治疗复发或难治多发性骨髓瘤.白血病.淋巴瘤.2009.18(6).364-366.核心期刊 |
17. 刘爱军,李利红*.不分泌型多发性骨髓瘤1 1例的临床及实验室特点.白血病.淋巴瘤.2009.18(1).21-22.核心期刊 |